M
Markus Hoffmann
Researcher at German Primate Center
Publications - 155
Citations - 23747
Markus Hoffmann is an academic researcher from German Primate Center. The author has contributed to research in topics: Medicine & Biology. The author has an hindex of 30, co-authored 103 publications receiving 14853 citations. Previous affiliations of Markus Hoffmann include University of Veterinary Medicine Hanover & University of Veterinary Medicine Vienna.
Papers
More filters
Posted ContentDOI
Heterologous ChAdOx1 nCoV-19 and BNT162b2 prime-boost vaccination elicits potent neutralizing antibody responses and T cell reactivity
Rüdiger Groß,Zanoni M,Alina Seidel,Carina Conzelmann,Andrea Gilg,Daniela Krnavek,Erdemci-Evin S,Benjamin Mayer,Markus Hoffmann,Markus Hoffmann,Stefan Pöhlmann,Stefan Pöhlmann,Beil A,Joris Kroschel,Bernd Jahrsdörfer,Bernd Jahrsdörfer,Hubert Schrezenmeier,Hubert Schrezenmeier,Frank Kirchhoff,Jan Münch,Janis A. Müller +20 more
TL;DR: Hu et al. as mentioned in this paper evaluated the reactogenicity, humoral and cellular immune responses towards different SARS-CoV-2 variants after a heterologous ChAdOx1 nCoV19 BNT162b2 prime-boost vaccination and analyzed a cohort of 26 individuals aged 25-46 (median 30.5) years that received a ChAd Ox 1 n CoV-19 prime followed by a BNT 162b2 boost after an 8-week interval.
Journal ArticleDOI
Therapeutic Application of alpha-1-antitrypsin in COVID-19.
Felix Ritzmann,Praneeth Chitirala,Nadine Krüger,Markus Hoffmann,Markus Hoffmann,Wei Zuo,Frank Lammert,Sigrun Smola,Naveh Tov,Noga Alagem,Philipp M. Lepper,Stefan Pöhlmann,Stefan Pöhlmann,Christoph Beisswenger,Christian Herr,Robert Bals +15 more
TL;DR: The aim of this study was to investigate whether AAT can be considered as a candidate for the treatment of COVID-19, and found that AAT inhibits the protease activity in a concentration between 1 and 5mg/ml in submersed, undifferentiated epithelial cells or organoids.
Journal ArticleDOI
The MEK1/2-inhibitor ATR-002 efficiently blocks SARS-CoV-2 propagation and alleviates pro-inflammatory cytokine/chemokine responses
D. Schreiber,Dorothee Viemann,Jennifer Schöning,Sebastian Schloer,Angeles Mecate Zambrano,Linda Brunotte,Aileen Faist,Michael Schöfbänker,Eike R. Hrincius,Helen Hoffmann,Markus Hoffmann,Stefan Pöhlmann,Ursula Rescher,Oliver Planz,Stephan Ludwig +14 more
TL;DR: In this article , the suitability of the rapid accelerated fibrosarcoma/mitogen-activated protein kinase/extracellular signal-regulated kinase (Raf/MEK/ERK) pathway as a druggable target in the treatment of SARS-CoV-2 infections was explored.
Journal ArticleDOI
The Tetherin Antagonism of the Ebola Virus Glycoprotein Requires an Intact Receptor-Binding Domain and Can Be Blocked by GP1-Specific Antibodies.
Constantin Brinkmann,Inga Nehlmeier,Kerstin Walendy-Gnirß,Julia Nehls,Mariana González Hernández,Markus Hoffmann,Xiangguo Qiu,Ayato Takada,Michael Schindler,Stefan Pöhlmann +9 more
TL;DR: LLOV, like EBOV, counteracts the antiviral effector protein tetherin via its glycoprotein (GP), suggesting that tetherin does not pose a defense against LLOV spread in human cells and provides evidence that antibodies directed against GP1 can interfere with tetherin counteraction.
Journal ArticleDOI
Surface glycoproteins of an African henipavirus induce syncytium formation in a cell line derived from an African fruit bat, Hypsignathus monstrosus
Nadine Krüger,Markus Hoffmann,Michael Weis,Jan Felix Drexler,Marcel A. Müller,Christine Winter,Victor M. Corman,Tim Gützkow,Christian Drosten,Andrea Maisner,Georg Herrler +10 more
TL;DR: Serological screening and detection of genomic RNA indicates that members of the genus Henipavirus are present not only in Southeast Asia but also in African fruit bats, and the M74 glycoproteins show functional similarities to glycoprotein of Nipah virus.